Cancer immunotherapy biotech Argos Therapeutics files for a $60 million IPO

By Renaissance Capital,

Shutterstock photo

Argos Therapeutics, which is developing immunotherapies for the treatment of cancer and infectious diseases, filed on Monday with the SEC to raise up to $60 million in an initial public offering. The Durham, NC-based company, which was founded in 1997 and booked $5 million in collaboration and grant revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol ARGS. Argos Therapeutics initially filed confidentially on November 12, 2013. Piper Jaffray, Stifel and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ARGS

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by